Healthcare Industry News: radiotherapy
News Release - April 18, 2019
ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to CanadaMinogue Medical to Serve as Exclusive Canadian Distributor for ViewRay's MRIdian System
CLEVELAND, April 18, 2019 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company has partnered with Minogue Medical Inc., a leading Canadian distributor of surgical devices, operating room disposables, hospital equipment, and simulators for medical education. As part of the exclusive distribution agreement, Minogue Medical will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system throughout Canada.
"The medical device market in Canada is strong and sophisticated, with a high demand for innovative medical technologies," said Jim Alecxih, Chief Commercial Officer at ViewRay. "We're pleased to partner with Minogue Medical to bring MRIdian to the Canadian healthcare system and improve the accuracy and precision of radiation therapy throughout the country."
Minogue Medical Inc., headquartered in Montreal, Quebec, is one the leading distributors of medical equipment in Canada. For more than 30 years, Minogue Medical has provided hospitals and medical clinics with value-driven, best-to-market products, and ensured continued assistance through a specialized field-based support team. The company's core values revolve around best patient care and delivery of state-of-the-art medical products.
"We are excited to continue to bring innovative technologies to Canadian hospitals and patients," said Danny Minogue, CEO of Minogue Medical Inc. "MRIdian's MRI-guided radiation therapy will help provide Canadians with accurate, efficient, optimized care to help ensure excellent outcomes for patients."
MRIdian provides continuous high-contrast imaging of soft tissue during radiation therapy treatment to help clinicians position the patient, track tumor and anatomical motion, and accurately target treatment. MRIdian also enables on-table adaptive therapy, which allows clinicians to adapt to changes and movement in the patient's anatomy in real-time while the patient is being treated, bringing even greater precision to radiation delivery.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.
Forward-Looking Statements: This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include, but are not limited to references to future MRIdian installations, clinical value and outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, government and regulatory uncertainty, including but not limited to obtaining authorizations to market and new tariffs and trade restrictions, and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEuropean Symposium to Advance Adoption of MRI-Guided Radiation Therapy
Patient Treatments with ViewRay's MRIdian Linac Begin in New England
ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers